PROTHENA CORPORATION PUBLIC LIMITED COMPANY Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
PROTHENA CORPORATION PUBLIC LIMITED COMPANY (PRTA) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$19.34 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-06
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was $21.93M.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was -$53.45M.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$72.32M.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$24.22M.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was -$163.86M.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was -$148.79M.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$91.58M, a 169.29% decline from fiscal 2022.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was $132.17M, a 53.19% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$19.34M 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $21.93M 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | -$163.86M 10-K · filed 2026-02-27 | |||
| 2025-09-30 | -$140.54M 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | -$99.95M 10-Q · filed 2026-08-06 | |||
| 2025-03-31 | -$53.45M 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | -$148.79M 10-K · filed 2026-02-27 | |||
| 2024-09-30 | -$100.92M 10-Q · filed 2025-11-06 | |||
| 2024-06-30 | -$56.06M 10-Q · filed 2025-08-04 | |||
| 2024-03-31 | -$72.32M 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | -$91.58M 10-K · filed 2026-02-27 | |||
| 2023-09-30 | -$39.51M 10-Q · filed 2024-11-12 | |||
| 2023-06-30 | -$51.30M 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | -$24.22M 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | $132.17M 10-K · filed 2025-02-27 | |||
| 2022-09-30 | -$83.47M 10-Q · filed 2023-11-02 | |||
| 2022-06-30 | -$70.30M 10-Q · filed 2023-08-03 | |||
| 2022-03-31 | -$36.10M 10-Q · filed 2023-05-04 | |||
| 2021-12-31 | $282.36M 10-K · filed 2024-02-22 | |||
| 2021-09-30 | $303.37M 10-Q · filed 2022-11-03 | |||
| 2021-06-30 | $104.45M 10-Q · filed 2022-08-08 | |||
| 2021-03-31 | $47.61M 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | -$80.34M 10-K · filed 2023-02-28 | |||
| 2020-09-30 | -$61.20M 10-Q · filed 2021-11-04 | |||
| 2020-06-30 | -$41.78M 10-Q · filed 2021-08-05 | |||
| 2020-03-31 | -$23.04M 10-Q · filed 2021-05-11 | |||
| 2019-12-31 | -$53.29M 10-K · filed 2022-02-25 | |||
| 2019-06-30 | -$29.52M 10-Q · filed 2019-08-06 | |||
| 2019-03-31 | -$17.55M 10-Q · filed 2019-05-07 | |||
| 2018-12-31 | $10.04M 10-K · filed 2021-02-26 | |||
| 2018-09-30 | $33.89M 10-Q · filed 2018-11-06 | |||
| 2018-06-30 | $68.59M 10-Q · filed 2019-08-06 | |||
| 2018-03-31 | $11.42M 10-Q · filed 2019-05-07 | |||
| 2017-12-31 | $30.70M 10-K · filed 2020-03-03 | |||
| 2017-09-30 | $69.14M 10-Q · filed 2018-11-06 | |||
| 2017-06-30 | $84.81M 10-Q · filed 2018-08-07 | |||
| 2017-03-31 | $119.63M 10-Q · filed 2018-05-09 | |||
| 2016-12-31 | $20.39M 10-K · filed 2019-03-15 | |||
| 2016-09-30 | $42.04M 10-Q · filed 2017-11-07 | |||
| 2016-06-30 | $76.42M 10-Q · filed 2017-08-09 | |||
| 2015-12-31 | $77.01M 10-K · filed 2018-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |